COV-CHIM01: SARS-CoV-2 (COVID-19) Dose Finding Infection Study
NCT ID: NCT04864548
Last Updated: 2023-01-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
132 participants
INTERVENTIONAL
2021-05-27
2024-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study
NCT06478420
SARS-CoV-2 Human Challenge Characterisation Study
NCT04865237
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
NCT04467151
First-in-Human Study of Orally Administered GS-441524 for COVID-19
NCT04859244
Home Usability Study of the SARS-CoV-2 (COVID-19) Test
NCT04395391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A Data Safety Monitoring Board (DSMB) will review safety and quantitative virology at each dose level and will recommend continuation based on emergent data.
Rescue treatment with a single course of oral Paxlovid will commence immediately after any warning symptoms or signs of COVID-19 disease beyond mild disease.
Once the optimal dose of wildtype SARS-CoV-2 has been identified for previously infected volunteers and uninfected vaccinated volunteers (dose escalation groups 1 and 3), further challenge infections in groups 2 and 4 may proceed.
Volunteers will remain in isolation rooms within the clinical trials unit for a minimum of 14 days post inoculation and until demonstration of the absence of live virus in two sequential samples. All 4 groups will together enrol up to 132 volunteers.
This study will be funded by the Wellcome Trust and Department of Health and Social Care (DHSC).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1A: Low dose challenge
Intranasal viral challenge with 1 x 10\^1 TCID\_50 in previously infected volunteers
N= 6-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 1B: Medium dose #1 challenge
Intranasal viral challenge with 1 x 10\^2 TCID\_50 in previously infected volunteers
N= 6-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 1C: Medium dose #2 challenge
Intranasal viral challenge with 1 x 10\^3 TCID\_50 in previously infected volunteers
N= 6-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 1D: Medium dose #3 challenge
Intranasal viral challenge with 1 x 10\^4 TCID\_50 in previously infected volunteers
N= 4-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 1E: High dose challenge
Intranasal viral challenge with 1 x 10\^5 TCID\_50 in previously infected volunteers
N= 4-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 2: Safety & Dose confirmation Group
Intranasal viral challenge with the dose identified from Group 1a-e (1x10\^1, 1x10\^2, 1x10\^3, 1x10\^4, or 1x10\^5 TCID\_50)
N=10-30 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 3a: Medium dose #1 challenge
Intranasal viral challenge with 1 x 10\^2 TCID\_50 in previously uninfected, vaccinated volunteers
N=6-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 3b: Medium dose #2 challenge
Intranasal viral challenge with 1 x 10\^3 TCID\_50 in previously uninfected, vaccinated volunteers
N=4-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 3c: Medium dose #3 challenge
Intranasal viral challenge with 1 x 10\^4 TCID\_50 in previously uninfected, vaccinated volunteers
N=4-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 3d: High dose challenge
Intranasal viral challenge with 1 x 10\^5 TCID\_50 in previously uninfected, vaccinated volunteers
N=4-8 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Group 4: Safety & Dose confirmation Group
Intranasal viral challenge with the dose identified from Group 3a-d (1x10\^2, 1x10\^3, 1x10\^4 or 1x10\^5 TCID\_50)
N=10-30 participants
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SARS-CoV-2 virus
The SARS-COV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with COVID-19. The isolate was plaque purified to obtain a 'single' virus entity. The selected plaque, B1, was subsequently manufactured in accordance with GMP at the Great Ormond Street manufacturing suite.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Body Mass Index (BMI) ≥18.5 kg/m2and ≤28 kg/m2.
Exclusion Criteria
5. Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner or any relevant health authority
6. Allow the investigator to register volunteer details with a confidential database (The Over-volunteering Prevention Service) to prevent concurrent entry into clinical studies/trials
7. Agreement to refrain from blood donation during the course of the study
8. a. For women of child bearing potential (WOCBP), a willingness to practice continuous effective contraception during the study and, a negative pregnancy test on the day(s) of screening and challenge b. b. For women of child bearing potential (WOCBP) taking the combined oral contraceptive pill, a willingness to use barrier contraception with spermicide during treatment with Paxlovid and for 30 days after completing Paxlovid treatment (should they receive it).
9. Able and willing (in the investigator's opinion) to comply with all study requirements
10. No clinically relevant findings in medical history or on physical examination in the opinion of a clinically qualified investigator, in discussion with the CI if needed
11. For Groups 1 \& 2: Previous microbiological confirmation of SARS-CoV-2 infection \> 3 months prior to enrolment (Proof of positive PCR or lateral flow antigen test confirmed via medical notes/ or UK HSA or a history from a volunteer consistent with SARS-CoV-2 infection with other evidence of this infection such as a photograph of a positive lateral flow test on the volunteer's phone or similar) OR serological confirmation such as positive anti-nucleocapsid IgG serology (unless this is explainable by prior vaccination) with the most recent history of symptoms or exposure likely to represent SARS-CoV-2 infection having occurred \> 3 months prior to enrolment.
12. For Groups 3 \& 4: Written or electronic evidence of at least one vaccination against SARS- CoV-2 \>21 days prior to enrolment (proof required would include written or electronic evidence from GP/ medical records or electronic NHS COVID pass) where no history of symptoms or exposure can be identified to determine the timing of SARS-CoV-2 infection, volunteers may be enrolled \>7 weeks from the identification of anti-nucleocapsid positivity and \>3 months from their last negative anti-nucleocapsid antibody test.
1\) History or evidence of any clinically significant or currently active cardiovascular, (including thromboembolic events), respiratory (excluding SARS CoV-2 infection), dermatological, gastrointestinal, endocrine, haematological, hepatic, immunological, rheumatological, metabolic, urological, renal, neurological or psychiatric illness. Specifically:
1. Volunteers with any history of physician diagnosed and/or objective test confirmed asthma, chronic obstructive pulmonary disease, pulmonary hypertension, reactive airway disease, or chronic lung condition of any aetiology or who have experienced:
i) Significant/severe wheeze in the past ii) Clinically significant respiratory symptoms including wheeze which has ever resulted in hospitalisation iii) Known bronchial hyper reactivity to viruses
2. History of thromboembolic, cardiovascular or cerebrovascular disease
3. History or evidence of diabetes mellitus (Type I or Type II)
4. Any concurrent serious illness including history of malignancy that could interfere with the aims of the study or a subject completing the study. Basal cell carcinoma within 5 years of treatment or with evidence of recurrence is also an exclusion.
5. Migraine with associated neurological symptoms such as hemiplegia or vision loss. Cluster headache/migraine or prophylactic treatment for migraine
6. History or evidence of clinically significant autoimmune disease or known immunodeficiency of any cause (including HIV).
7. History of severe psychiatric illness at any time (e.g. inpatient stay, psychosis) or current significant active symptoms of anxiety and/or depression or significant claustrophobia. Consider exclusion in the following cases:
i) Volunteers with history of anxiety related symptoms of any severity within the last 2 years if the Generalized Anxiety Disorder-7 score is ≥5 ii) Volunteers with a history of depression of any severity within the last 2 years if the Patient Health Questionnaire-9 score is ≥4 iii) Significant claustrophobia
8. Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following injections or venepuncture.
9. Other major disease that, in the opinion of the Investigator, could interfere with a subject completing the study and necessary investigations.
2\) Clinically significant smoking history. Defined as: Current smoker (any smoking including e-cigarettes in the last 3 months) or \> 2 pack year smoking history at any time (2 pack years is equivalent to 20 cigarettes daily for 2 years), or use of any nicotine containing products, on more than one occasion, within the last 3 months.
3\) History or presence of alcohol addiction, or excessive use of alcohol (average weekly intake in excess of 28 units alcohol; one unit being a half glass of beer, a small glass of wine or a measure of spirits)
4\) Clinically significant history of use of drugs of misuse, with evidence of a negative drugs of misuse urine test required at screening and quarantine admission
5\) History of anaphylaxis or any allergy likely to be worsened by any component of the study agent or proposed treatment regime.
6\) Clinically active rhinitis (including hay fever) or history of moderate to severe rhinitis, or history of seasonal allergic rhinitis likely to be active at time of inclusion into the study and/or requiring regular nasal corticosteroids on at least weekly basis, within 30 days of admission to quarantine.
7\) Any significant abnormality altering the anatomy of the nose or nasopharynx, clinically significant history of epistaxis (nose bleeds) or any nasal or sinus surgery within six months of inoculation
8\) Clinical, radiological, or laboratory evidence of current active TB disease or latent TB infection
9\) Previous VZV pneumonia
10\) Positive HBsAg, HCV or HIV antibodies
11\) Concurrent use of oral, inhaled or systemic steroid medication or use within the last 6 months (steroids used as a cream or ointment are permissible), or the use of other immunosuppressive agents concurrently or within the last 6 months.
12\) Concurrent use of medication contraindicated for use with Paxlovid rescue therapy
13\) Administration of immunoglobulins and/or any blood products within the three months preceding the planned study challenge date
14\) Current use of any medication or other drug taken through the nasal or inhaled route including cocaine or other recreational drugs
15\) Plans to receive a live vaccination 30 days prior to enrolment, or any vaccination (i.e. non-live, including a SARS-CoV-2 vaccine) 21 days prior to enrolment and/or plans to take any vaccination 30 days following enrolment
16\) Current pregnancy or pregnancy within the last 6 months, lactation or intention to become pregnant during study period
17\) Shares a household with someone with clinically significant immunodeficiency (due to underlying medical condition, medication or pregnancy); or who is extremely clinically vulnerable (previously shielding under Public Health England (now referred to as UK HSA) guidelines)
18\) Concurrent participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
19\) Laboratory confirmed (PCR or lateral flow antigen test) SARS-Cov-2 infection, evidence of viral pneumonitis on chest radiograph or a high clinical suspicion of COVID-19 disease in the 3 months preceding enrolment.
20\) Post COVID-19 symptoms that have not resolved by 1 month prior to enrolment
21\) Previous hospitalisation with COVID-19 disease or related complications e.g. pulmonary fibrosis on chest x ray
22\) Family history of 1st degree relative aged 50 years or less with sudden cardiac or unexplained death
23\) Family history of severe COVID-19 disease or response to any other viral disease e.g. Guillain-Barré
24\) Family history unavailable or in opinion of investigators not sufficient to assess criteria 22 and 23.
25\) Clinically significant abnormality on screening chest radiograph
26\) Clinically significant abnormality of lung function testing
27\) Clinically significant structural heart disease detected on CMR or echocardiogram, such as abnormal ventricular systolic function, evidence of previous myocardial infarction, previous myocarditis (on CMR) or significant valvular heart disease (more than mild)
28\) Any clinically significant abnormality of screening blood or urine tests
29\) Any other significant disease, disorder, or finding, which, in the opinion of the investigator, may either put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data
30\) Venous access deemed inadequate for the phlebotomy and cannulation demands of the study.
For Groups 3 \& 4:
31\) Previous positive test for SARS CoV-2 infection (PCR or lateral flow antigen test) or a high clinical suspicion of COVID-19 disease at any time.
32\) Positive Anti-nucleocapsid IgG at screening, unless explainable by vaccination
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Helen McShane, MD and PhD
Role: PRINCIPAL_INVESTIGATOR
University of Oxford
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oxford Clinical Research Facility (OxCRF)
Oxford, Oxon, United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine
Oxford, Oxon, United Kingdom
Oxford University Hospital NHS Trust
Oxford, Oxon, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Prof. Helen McShane, MD and PhD
Role: primary
Prof. Helen McShane, MD and PhD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Jackson S, Marshall JL, Mawer A, Lopez-Ramon R, Harris SA, Satti I, Hughes E, Preston-Jones H, Cabrera Puig I, Longet S, Tipton T, Laidlaw S, Doherty RP, Morrison H, Mitchell R, Tanner R, Ateere A, Stylianou E, Wu MS, Fredsgaard-Jones TPW, Breuer J, Rapeport G, Ferreira VM, Gleeson F, Pollard AJ, Carroll M, Catchpole A, Chiu C, McShane H; COV-CHIM01 study team. Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study. Lancet Microbe. 2024 Jul;5(7):655-668. doi: 10.1016/S2666-5247(24)00025-9. Epub 2024 May 1.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COV-CHIM01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.